论文部分内容阅读
目的探讨头孢哌酮舒巴坦治疗耐药淋病的疗效,并与头孢曲松相对照。方法确诊为耐药淋病患者115例,随机分为治疗组(头孢哌酮舒巴坦)58例,对照组(头孢曲松)57例。治疗组以头孢哌酮舒巴坦2.0静脉注射,1次/d,连用2d;对照组,以头孢曲松1g静脉注射,1次/d,连用2d。结果治疗组:总有效率93.1%,细菌消除率93.1%,不良反应率6.9%,对照组:总有效率96.5%,细菌消除率96.5%,不良反应率8.77%。2组总有效率,差异无统计学意义。结论头孢哌酮舒巴坦治疗耐药淋病安全有效。
Objective To investigate the efficacy of cefoperazone-sulbactam in the treatment of drug-resistant gonorrhea and compare it with ceftriaxone. Methods One hundred and fifteen patients diagnosed as drug resistant gonorrhea were randomly divided into treatment group (cefoperazone sulbactam) 58 cases and control group (ceftriaxone 57 cases). The treatment group was cefoperazone sulbactam 2.0 intravenously once a day for 2 days. The control group was given ceftriaxone 1 g intravenously once daily for 2 days. Results In the treatment group, the total effective rate was 93.1%, the bacterial elimination rate was 93.1% and the adverse reaction rate was 6.9%. In the control group, the total effective rate was 96.5%, the bacterial elimination rate was 96.5% and the adverse reaction rate was 8.77%. The total effective rate of 2 groups, the difference was not statistically significant. Conclusion Cefoperazone sulbactam is safe and effective in the treatment of resistant gonorrhea.